GRAIL, Inc. (NASDAQ:GRAL) Receives Average Rating of “Hold” from Analysts

GRAIL, Inc. (NASDAQ:GRAL) has earned a consensus rating of “Hold” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $107.8333.

Several brokerages have commented on GRAL. Canaccord Genuity Group increased their price target on GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a report on Monday, November 17th. Guggenheim upped their price objective on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Robert W. Baird assumed coverage on shares of GRAIL in a report on Tuesday. They issued an “outperform” rating and a $113.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Finally, Morgan Stanley raised their price target on GRAIL from $85.00 to $110.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st.

GRAIL Stock Performance

Shares of NASDAQ GRAL opened at $102.28 on Thursday. The business’s 50-day simple moving average is $97.29 and its 200-day simple moving average is $75.64. GRAIL has a 52 week low of $20.44 and a 52 week high of $118.84. The firm has a market cap of $3.99 billion, a price-to-earnings ratio of -8.79 and a beta of 4.52.

Institutional Investors Weigh In On GRAIL

Several hedge funds have recently modified their holdings of GRAL. Caxton Associates LLP bought a new position in GRAIL during the second quarter worth $3,320,000. NWF Advisory Services Inc. bought a new position in GRAIL during the second quarter valued at about $1,062,000. Y Intercept Hong Kong Ltd acquired a new position in GRAIL in the 3rd quarter valued at approximately $885,000. Legal Advantage Investments Inc. bought a new stake in shares of GRAIL in the 3rd quarter worth approximately $1,242,000. Finally, Sheets Smith Investment Management bought a new stake in shares of GRAIL in the 3rd quarter worth approximately $1,689,000.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.